Literature DB >> 23651026

CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population.

Francesco M Carpi1, Silvia Vincenzetti, Jessica Ubaldi, Stefania Pucciarelli, Valeria Polzonetti, Daniela Micozzi, Fiorenzo Mignini, Valerio Napolioni.   

Abstract

AIM: To assess the distribution of CDA activity from whole blood of 142 healthy subjects, determining its main predictors among genetic (six CDA SNPs) and physiological factors (age and gender). Moreover, we performed a kinetic study of the two CDA protein variants (Q27 and K27) determined by the rs2072671 SNP. MATERIALS &
METHODS: CDA activity was assessed by HPLC. Selected CDA SNPs were genotyped by PCR-based methods. Recombinant CDA protein variants (Q27 and K27) were expressed in an Escherichia coli strain SØ5201 and kinetic assays were performed.
RESULTS: The mean value of CDA activity was 0.051 ± 0.024 mU/mg and followed a normal distribution in the study population. Carriers of the CDA*2B (-451T/-92G/-31Del/79C/435C) haplotype displayed higher CDA activity compared with the others. CDA -451G>A, -92A>G and 79A>C (K27Q) SNPs displayed significant associations with CDA activity. The best predictive model of CDA activity included the variables gender and CDA 79A>C (K27Q). Cytidine is the preferential substrate for the variant Q27.
CONCLUSION: We suggest the analysis of both CDA activity and CDA 79A>C (K27Q) SNP in future prospective trials with cytidine analogs, alone or in combination, in order to identify the best marker to secure the administration of these anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651026     DOI: 10.2217/pgs.13.56

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  9 in total

Review 1.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

2.  An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).

Authors:  Federico Innocenti; Chen Jiang; Alexander B Sibley; Stefanie Denning; Amy S Etheridge; Dorothy Watson; Donna Niedzwiecki; Ace J Hatch; Herbert I Hurwitz; Andrew B Nixon; Yoichi Furukawa; Michiaki Kubo; Daniel J Crona; Hedy L Kindler; Howard L McLeod; Mark J Ratain; Kouros Owzar
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

3.  Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.

Authors:  Jun Amaki; Makoto Onizuka; Ken Ohmachi; Yasuyuki Aoyama; Ryujiro Hara; Akifumi Ichiki; Hidetsugu Kawai; Ai Sato; Mitsuki Miyamoto; Masako Toyosaki; Shinichiro Machida; Minoru Kojima; Yukari Shirasugi; Hiroshi Kawada; Yoshiaki Ogawa; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2015-03-04       Impact factor: 2.490

4.  Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.

Authors:  R Cohen; L H Preta; V Joste; E Curis; O Huillard; A Jouinot; C Narjoz; A Thomas-Schoemann; A Bellesoeur; M Tiako Meyo; J Quilichini; D Desaulle; I Nicolis; A Cessot; M Vidal; F Goldwasser; J Alexandre; B Blanchet
Journal:  Br J Clin Pharmacol       Date:  2019-01-30       Impact factor: 4.335

5.  PharmGKB summary: gemcitabine pathway.

Authors:  Maria L Alvarellos; Jatinder Lamba; Katrin Sangkuhl; Caroline F Thorn; Liewei Wang; Daniel J Klein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-11       Impact factor: 2.089

6.  Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.

Authors:  Xandra García-González; Lucía Cortejoso; María I García; Pilar García-Alfonso; Luis Robles; Cristina Grávalos; Eva González-Haba; Pellicer Marta; María Sanjurjo; Luis A López-Fernández
Journal:  Oncotarget       Date:  2015-03-20

7.  Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.

Authors:  Aurora Medina-Sanson; Arturo Ramírez-Pacheco; Silvia Selene Moreno-Guerrero; Elisa María Dorantes-Acosta; Metzeri Sánchez-Preza; Alfonso Reyes-López
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

Review 8.  Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Marta Alonso-Peña; Anabel Sanchez-Martin; Paula Sanchon-Sanchez; Meraris Soto-Muñiz; Ricardo Espinosa-Escudero; Jose J G Marin
Journal:  Cancer Drug Resist       Date:  2019-09-19

9.  CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells.

Authors:  Xiao-Fang Wei; You-Fan Feng; Qiao-Lin Chen; Qi-Ke Zhang
Journal:  Cancer Cell Int       Date:  2018-07-09       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.